Product image of Lamivudina E Zidovudina Aurobindo (Zidovudine, Lamivudine) supplied by GNH India

Lamivudina E Zidovudina Aurobindo

Active Ingredient:
Zidovudine, Lamivudine
Origin:
EU

Lamivudina E Zidovudina Aurobindo (Zidovudine, Lamivudine)

Lamivudine and Zidovudine, the active ingredients in Lamivudina E Zidovudina Aurobindo, are nucleoside reverse transcriptase inhibitors presented as an oral dosage form for systemic use. They treat HIV‑1 infection in adults and adolescents and are used to prevent mother‑to‑child transmission of HIV.

GNH India supplies Lamivudina E Zidovudina Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Aurobindo Pharma (Italia) S.R.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lamivudine/Zidovudine is an antiretroviral combination that targets HIV replication.

  • HIV‑1 infection in adults and adolescents: reduces viral load and improves immune function when used as part of combination therapy.
  • Prevention of mother‑to‑child transmission of HIV: lowers the risk of vertical transmission when administered to pregnant women.
  • Chronic HIV management: maintains virologic suppression as part of a lifelong treatment regimen.

How It Works

  • Lamivudine and zidovudine are nucleoside analog reverse transcriptase inhibitors. After oral absorption, they are phosphorylated intracellularly to active triphosphate forms, which compete with natural nucleotides and become incorporated into viral DNA. This incorporation causes premature chain termination, halting HIV reverse transcription and preventing viral replication.

Side Effects

Both agents are generally well tolerated, but adverse reactions can occur.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal discomfort.
  • Headache: transient cranial pain.
  • Fatigue: general tiredness.
  • Anemia: reduced red blood cell count, especially with zidovudine.
  • Neutropenia: lowered neutrophil count.
  • Diarrhea: loose stools.

Serious or Rare Side Effects

  • Lactic acidosis: metabolic disturbance requiring immediate care.
  • Severe hepatotoxicity: liver enzyme elevations and jaundice.
  • Myopathy: muscle weakness and pain.
  • Pancreatitis: inflammation of the pancreas.
  • Stevens‑Johnson syndrome: severe skin reaction.
  • Bone marrow suppression: pancytopenia requiring monitoring.

Precautions & Warnings

Use of lamivudine/zidovudine requires careful clinical monitoring.

  • Pregnancy: Category C – weigh potential benefits against risks and consult obstetric specialist.
  • Breastfeeding: caution advised; drug may be excreted in milk.
  • Hepatic impairment: dose adjustment may be needed; monitor liver function tests.
  • Renal impairment: assess renal function regularly; adjust dosing if required.
  • Concomitant anemia or neutropenia: monitor blood counts closely.
  • Store at below 25°C: keep in original container, protect from moisture and direct sunlight.

Avoid Interactions

Lamivudine/zidovudine may interact with several drug classes.

Major Interactions (Avoid)

  • Didanosine: increased risk of severe peripheral neuropathy and pancreatitis.
  • Stavudine: heightened mitochondrial toxicity.
  • Mycophenolate mofetil: reduced efficacy of antiretroviral therapy.

Moderate Interactions (Monitor Closely)

  • Trimethoprim‑sulfamethoxazole: additive bone marrow suppression.
  • Rifampicin: may lower plasma concentrations of zidovudine.
  • NSAIDs: potential for renal function impact when combined with tenofovir‑based regimens.

Frequently Asked Questions

Lamivudina E Zidovudina Aurobindo is a fixed‑dose combination of lamivudine and zidovudine used to treat HIV‑1 infection in adults and adolescents and to prevent mother‑to‑child transmission of HIV when given to pregnant women.

Both drugs are nucleoside reverse transcriptase inhibitors. After oral absorption they are converted inside cells to active triphosphate forms that compete with natural nucleotides, become incorporated into viral DNA, and cause chain termination, thereby blocking HIV replication.

The prescribed dose is determined by the treating physician based on the patient’s clinical status, weight, renal and hepatic function, and concomitant medications. Patients should follow the exact regimen provided by their healthcare professional.

The product is classified as Pregnancy Category C. It may be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution is advised during breastfeeding because the drugs can be excreted in breast milk; a healthcare provider should evaluate the risk‑benefit ratio.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lamivudine/zidovudine is a nucleoside reverse transcriptase inhibitor regimen that offers a well‑established efficacy profile and is often used in resource‑limited settings. Compared with newer agents such as integrase inhibitors, it may have a different side‑effect spectrum, including higher rates of anemia and neutropenia, but remains a cost‑effective option in many treatment guidelines.

Store the product at temperatures below 25 °C in its original packaging. Protect it from moisture, direct sunlight and extreme heat to maintain stability and potency.

The medication is taken orally, usually with food or a glass of water, as directed by the prescribing clinician. Swallow tablets whole; do not crush or chew unless specifically instructed.

Serious adverse events include lactic acidosis, severe hepatotoxicity, bone‑marrow suppression leading to pancytopenia, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for signs of these conditions.

Patients with known hypersensitivity to lamivudine, zidovudine, or any excipients in the formulation should avoid the product. Those with severe anemia, neutropenia, or uncontrolled hepatic disease should be evaluated carefully before initiation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Zidovudine, Lamivudine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT